Gastroparesis Registry 3

Who can take part

• Symptoms of gastroparesis of at least 12 weeks' duration with varying degrees of nausea, vomiting, early satiety, postprandial fullness
• An etiology of either diabetic, idiopathic, or post-fundoplication (Nissen, Dor, or Toupet) gastroparesis or gastroparesis-like disorder (symptoms of gastroparesis but normal gastric emptying)
• Gastric emptying scintigraphy of solids using the 4-hour Egg Beaters® protocol (or equivalent generic liquid egg white meal) within the last 6 months with either:
• Abnormal gastric emptying rate defined as an abnormal 2 hour (>60% retention) and/or 4 hour (>10% retention) result based on a 4 hour scintigraphic gastric emptying study. (This group will comprise ~75% of patients in the registry.)
• Patients with a normal gastric emptying rate, but who have symptoms of gastroparesis. (This group will comprise ~25% of patients in the registry.)
• Negative upper endoscopy or upper radiographic GI series within 2 years of registration
• Age at least 18 years at initial screening visit

Who cannot take part

• Prior gastric surgery including total or subtotal (near complete) gastric resection, esophagectomy, gastrojejunostomy, gastric bypass, gastric sleeve, pyloroplasty, pyloromyotomy. Note: patients with prior Nissen, Dor, or Toupet fundoplication will be eligible for enrollment
• Inability to comply with or complete the gastric emptying test by scintigraphy (including allergy to eggs)
• Presence of other conditions that could explain the patient's symptoms:
• Active inflammatory bowel disease
• Primary neurological conditions that can cause nausea and vomiting such as increased intracranial pressure, space occupying or inflammatory/infectious lesions
• Acute renal failure
• Acute liver failure
• Advanced liver disease (Child's B or C; a Child-Pugh-Turcotte (CPT) score of ≥7)
• Any other condition, which in the opinion of the investigator, could explain the symptoms or interfere with study requirements
• Chronic renal failure (serum creatinine >3 mg/dL) and/or on hemodialysis or peritoneal dialysis
• Use of narcotic analgesics greater than three days per week
• Pyloric or intestinal obstruction: by EGD, UGI, or Abdominal CT
• Known eosinophilic gastroenteritis or eosinophilic esophagitis
• Inability to obtain informed consent